Last reviewed · How we verify
Intramuscular aripiprazole, olanzapine
Aripiprazole and olanzapine are atypical antipsychotics that modulate dopamine and serotonin signaling in the brain to reduce psychotic symptoms and stabilize mood.
Aripiprazole and olanzapine are atypical antipsychotics that modulate dopamine and serotonin signaling in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia (maintenance treatment via intramuscular injection), Bipolar I disorder (maintenance treatment via intramuscular injection).
At a glance
| Generic name | Intramuscular aripiprazole, olanzapine |
|---|---|
| Also known as | Aripiprazole -> Olanzapine |
| Sponsor | Veterans Medical Research Foundation |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Aripiprazole acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A partial agonist, while olanzapine is a dopamine D2 and serotonin 5-HT2A receptor antagonist. Both agents work through different mechanisms but converge on reducing hyperactivity in mesolimbic and mesocortical dopamine pathways implicated in psychosis, while the intramuscular formulation provides sustained therapeutic levels for improved medication adherence in patients with schizophrenia or bipolar disorder.
Approved indications
- Schizophrenia (maintenance treatment via intramuscular injection)
- Bipolar I disorder (maintenance treatment via intramuscular injection)
Common side effects
- Weight gain
- Sedation
- Akathisia
- Extrapyramidal symptoms
- Metabolic syndrome
- Injection site reactions
- Orthostatic hypotension
Key clinical trials
- Examining the Effects of Antipsychotic Medications on Insulin Sensitivity (PHASE4)
- Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: